Retrospective Study to Collect Follow-Up Data at 12 Months Among Transplant Recipients with Refractory or Resistant Cytomegalovirus Infections Randomized to the Maribavir Treatment Arm in the SHP620-303 Open-Label Phase III Trial

Grants and Contracts Details

StatusFinished
Effective start/end date5/1/217/21/22

Funding

  • PPD Investigator Services LLC: $10,588.00